Ainos Regains Nasdaq Compliance, Sets 90-Day Roadmap to Scale AI Nose Platform in 2026
Ainos (NASDAQ:AIMD) has regained Nasdaq compliance and unveiled its 90-day roadmap for scaling its AI Nose platform. The company reported significant achievements, including a 412% year-over-year revenue increase in Q1 2025 and strategic partnerships with major industry players like ASE Technology Holding for deploying up to 15,000 AI Nose units.
The company's proprietary smell language model (SLM) has achieved 90% accuracy in classifying everyday scents, while its senior care program improved to 85% accuracy. Key partnerships with Kenmec and Solomon aim to integrate AI-powered scent intelligence into smart factory systems. The company also completed the first-ever integration of AI Nose with a humanoid robot through ugo Inc.
Ainos's 90-day plan focuses on deploying 1,400 AI Nose units with ASEH, expanding to 5,000 units, and launching SmellTech-as-a-Service (SaaS) as a subscription-based revenue model.
Ainos (NASDAQ:AIMD) ha riconquistato la conformità al Nasdaq e ha presentato la sua roadmap di 90 giorni per espandere la piattaforma AI Nose. L'azienda ha riportato risultati significativi, tra cui un aumento del fatturato del 412% su base annua nel primo trimestre 2025 e collaborazioni strategiche con importanti attori del settore come ASE Technology Holding per il dispiegamento di fino a 15.000 unità AI Nose.
Il modello proprietario di linguaggio degli odori (SLM) ha raggiunto una precisione del 90% nella classificazione degli odori quotidiani, mentre il programma per l'assistenza agli anziani ha migliorato la sua precisione all'85%. Partnership chiave con Kenmec e Solomon puntano a integrare l'intelligenza olfattiva basata su AI nei sistemi di fabbrica intelligenti. L'azienda ha inoltre completato la prima integrazione di AI Nose con un robot umanoide tramite ugo Inc.
Il piano di 90 giorni di Ainos si concentra sul dispiegamento di 1.400 unità AI Nose con ASEH, l'espansione a 5.000 unità e il lancio di SmellTech-as-a-Service (SaaS) come modello di ricavi basato su abbonamento.
Ainos (NASDAQ:AIMD) ha recuperado el cumplimiento con Nasdaq y ha presentado su hoja de ruta de 90 días para escalar su plataforma AI Nose. La compañía reportó logros significativos, incluyendo un aumento del 412% en ingresos interanuales en el primer trimestre de 2025 y alianzas estratégicas con grandes actores de la industria como ASE Technology Holding para desplegar hasta 15,000 unidades AI Nose.
El modelo propietario de lenguaje de olores (SLM) alcanzó una precisión del 90% en la clasificación de olores cotidianos, mientras que su programa de cuidado para personas mayores mejoró a una precisión del 85%. Asociaciones clave con Kenmec y Solomon buscan integrar inteligencia olfativa potenciada por IA en sistemas de fábricas inteligentes. La empresa también completó la primera integración de AI Nose con un robot humanoide a través de ugo Inc.
El plan de 90 días de Ainos se centra en desplegar 1,400 unidades AI Nose con ASEH, expandirse a 5,000 unidades y lanzar SmellTech-as-a-Service (SaaS) como modelo de ingresos basado en suscripción.
Ainos (NASDAQ:AIMD)가 나스닥 규정을 재충족하고 AI Nose 플랫폼 확장을 위한 90일 로드맵을 공개했습니다. 회사는 2025년 1분기 매출이 전년 대비 412% 증가하는 등 중요한 성과를 보고했으며, ASE Technology Holding과 같은 주요 산업 파트너와 최대 15,000대의 AI Nose 장치 배치를 위한 전략적 협력을 체결했습니다.
회사의 독자적인 냄새 언어 모델(SLM)은 일상적인 향기 분류에서 90% 정확도를 달성했으며, 노인 케어 프로그램은 85% 정확도로 개선되었습니다. Kenmec 및 Solomon과의 주요 파트너십은 AI 기반 향기 인텔리전스를 스마트 공장 시스템에 통합하는 것을 목표로 합니다. 또한 ugo Inc.를 통해 AI Nose와 휴머노이드 로봇의 최초 통합을 완료했습니다.
Ainos의 90일 계획은 ASEH와 함께 1,400대의 AI Nose 장치를 배치하고 5,000대로 확장하며, 구독 기반 수익 모델로 SmellTech-as-a-Service(SaaS)를 출시하는 데 중점을 둡니다.
Ainos (NASDAQ:AIMD) a retrouvé sa conformité au Nasdaq et a dévoilé sa feuille de route sur 90 jours pour développer sa plateforme AI Nose. L'entreprise a annoncé des réalisations majeures, notamment une augmentation de 412% du chiffre d'affaires en glissement annuel au premier trimestre 2025 et des partenariats stratégiques avec des acteurs majeurs comme ASE Technology Holding pour le déploiement de jusqu'à 15 000 unités AI Nose.
Le modèle propriétaire de langage olfactif (SLM) a atteint une précision de 90% dans la classification des odeurs courantes, tandis que son programme de soins aux personnes âgées a amélioré sa précision à 85%. Des partenariats clés avec Kenmec et Solomon visent à intégrer l'intelligence olfactive pilotée par IA dans les systèmes d'usines intelligentes. L'entreprise a également réalisé la première intégration d'AI Nose avec un robot humanoïde via ugo Inc.
Le plan sur 90 jours d'Ainos se concentre sur le déploiement de 1 400 unités AI Nose avec ASEH, une extension à 5 000 unités, et le lancement de SmellTech-as-a-Service (SaaS) en tant que modèle de revenus par abonnement.
Ainos (NASDAQ:AIMD) hat die Nasdaq-Konformität wiedererlangt und seinen 90-Tage-Fahrplan zur Skalierung seiner AI Nose-Plattform vorgestellt. Das Unternehmen meldete bedeutende Erfolge, darunter einen Umsatzanstieg von 412 % im Jahresvergleich im ersten Quartal 2025 sowie strategische Partnerschaften mit großen Branchenakteuren wie ASE Technology Holding zur Bereitstellung von bis zu 15.000 AI Nose-Einheiten.
Das firmeneigene Geruchssprachmodell (SLM) erreichte eine 90%ige Genauigkeit bei der Klassifizierung alltäglicher Düfte, während das Senior Care-Programm auf 85% Genauigkeit verbessert wurde. Wichtige Partnerschaften mit Kenmec und Solomon zielen darauf ab, KI-gestützte Duftintelligenz in intelligente Fabriksysteme zu integrieren. Außerdem wurde die erste Integration von AI Nose mit einem humanoiden Roboter über ugo Inc. abgeschlossen.
Der 90-Tage-Plan von Ainos konzentriert sich auf die Bereitstellung von 1.400 AI Nose-Einheiten mit ASEH, eine Erweiterung auf 5.000 Einheiten und die Einführung von SmellTech-as-a-Service (SaaS) als abonnementbasiertes Einnahmemodell.
- 412% year-over-year revenue growth in Q1 2025
- Strategic partnership with ASE Technology for deployment of up to 15,000 AI Nose units
- Smell language model achieved 90% accuracy in scent classification
- Regained Nasdaq compliance, maintaining $1.00+ share price for 10 consecutive days
- Successfully integrated AI Nose with humanoid robot platform
- Senior care program accuracy improved to 85%
- Large-scale commercialization not expected until 2026
- Initial deployment limited to 1,400 units in pilot phase
Insights
Ainos regains Nasdaq compliance while rapidly advancing its AI Nose technology with major partnerships and impressive 412% YoY revenue growth.
Ainos has successfully addressed a critical financial concern by regaining Nasdaq compliance, removing an immediate delisting threat that typically signals serious financial distress. This development provides essential stability for the company's future fundraising and investor confidence.
The company's AI Nose platform, powered by their proprietary smell language model (SLM), is showing promising commercial traction through three strategic partnerships: ASE Technology Holding (targeting up to
Particularly noteworthy is the
Their smell language model's
The 90-day execution plan focuses on concrete deployments rather than just R&D, with the first phase targeting approximately 1,400 AI Nose units with ASEH, followed by expansion to 5,000 units. The company's shift toward a SmellTech-as-a-Service (SaaS) subscription model could create more predictable recurring revenue streams if successfully implemented.
While Ainos appears to be making technical progress, their current focus on partnerships in Asia suggests they're still in early market penetration phases. The projected timeline for large-scale commercialization by 2026 indicates investors should expect continued development costs before potential profitability.
Commercial Momentum Accelerates with Partnerships to Drive AI-Powered Scent Intelligence for IndustrialAI and HealthcareAI
SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 16, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization, today announced it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The compliance confirmation comes as Ainos gains momentum across its AI Nose platform, with strategic deployments, commercial partnerships, and a 90-day execution plan aimed at enabling large-scale commercialization by 2026.
"Over the past six months, we optimized our capital structure and delivered key milestones for the AI Nose platform, powered by our proprietary smell language model (SLM). We are positioning for a phase of accelerated deployment and scalable revenue generation across industrial, robotics, and healthcare sectors," said Eddy Tsai, Chairman and CEO of Ainos.
Recent AI Nose Milestones Driving Growth
Strategic partnership with ASE Technology Holding (ASEH), the world's largest semiconductor packaging and testing company, with a targeted phased deployment plan of up to 15,000 AI Nose units.
Expanded industrial footprint through partnerships with Kenmec and Solomon, aiming to integrate AI-powered scent intelligence powered by AI Nose and smell language model (SLM) into smart factory and machine vision ecosystems across Asia.
Completed the world's first integration of AI Nose with a humanoid robot, for embedding digital olfactory sensing capabilities into ugo Inc.'s service robotics platform.
Smell language model (SLM) surpassed
90% accuracy in classifying everyday scents, including meat, food, and beverages.Senior care program improved accuracy to ~
85% from ~80% .412% year-over-year revenue increase in Q1 2025, driven by initial AI Nose sales for the senior care program.
Key Strategic Priorities for the Next 90 Days
Building toward its 2026 scale-up, Ainos will focus on the following near-term priorities:
Complete pilot deployment of approximately 1,400 AI Nose units with ASEH and initiate Phase 1 expansion to approximately 5,000 units.
With Kenmec, exhibit the AI Nose integrated ugo robot at Automation Taipei, to be held August 20-23 in Taiwan.
Drive SmellTech-as-a-Service (SaaS) as a subscription-based revenue model for AI Nose deployments and Smell ID services.
Enhance SLM performance through broad-scale validation and expanded real-world testing.
Pursue additional strategic partnerships in Asia and Europe for technology licensing and regional commercialization.
"Regaining Nasdaq compliance is just the beginning," Tsai added. "Our mission is to build a scalable, multi-revenue platform powered by scent intelligence, transforming smell into computable, actionable business data across global markets. I believe smell will be AI's next token."
On July 15, 2025, the Company received formal notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") confirming that Ainos' common stock maintained a closing bid price of
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What caused Ainos (AIMD) stock to regain Nasdaq compliance in July 2025?
How many AI Nose units will ASE Technology deploy in their partnership with Ainos?
What was Ainos (AIMD) revenue growth in Q1 2025?
What is the accuracy rate of Ainos' smell language model (SLM)?
What are Ainos' key strategic priorities for the next 90 days in 2025?
